A 30-year-old woman with a Gravida 2 Para 0 pregnancy status presents with menorrhagia and hypertension. What is the best treatment for her?
A 14-year-old girl presents with vaginal bleeding and occasional amenorrhea. What is the next step in management?
What is the treatment for dysfunctional uterine bleeding (DUB) in a 32-year-old multiparous woman?
Dysfunctional uterine bleeding is commonly encountered in all of the following except:
Dysfunctional uterine bleeding is defined as a state of abnormal uterine bleeding without any clinically detectable?
Primary amenorrhea is defined as the absence of menstruation by which age?
What is the drug of choice in the management of puberty menorrhagia?
A woman has 20 ml menstrual blood loss every 35 days. What is her condition?
In a case of dysfunctional uterine bleeding, which hormone is usually deficient?
A 20-year-old woman gives a history of sharp pain in the lower abdomen for 2-3 days every month approximately 2 weeks before the menses. What is the most probable etiology for her pain?
Explanation: ### Explanation The patient presents with **menorrhagia** (Heavy Menstrual Bleeding - HMB) and comorbid **hypertension**. According to the FIGO and NICE guidelines, the **Levonorgestrel-releasing intrauterine system (LNG-IUS/Mirena)** is the first-line medical management for HMB when no structural pathology is present. **Why Option B is Correct:** The LNG-IUS provides local progestogen effect, leading to profound endometrial atrophy and a significant reduction in menstrual blood loss (up to 90% at 6 months). In this patient, it is particularly advantageous because it is **non-hormonal in its systemic effect**, making it safe for patients with hypertension, unlike estrogen-containing options. **Why Other Options are Incorrect:** * **Option A (COCPs):** These are contraindicated or should be used with extreme caution in patients with hypertension due to the estrogen component, which can further increase blood pressure and the risk of thromboembolic events. * **Option C (Hysterectomy):** This is a definitive surgical treatment but is reserved for patients who have completed their family or when medical/less invasive treatments fail. This patient is G2P0, suggesting she may still desire future fertility. * **Option D (TCRE):** Endometrial ablation/resection is a second-line surgical option for those who do not wish to conceive. It is generally avoided in women who still desire pregnancy. **Clinical Pearls for NEET-PG:** * **First-line for HMB:** LNG-IUS (Mirena). * **Mechanism of LNG-IUS:** Local release of 20μg levonorgestrel/day → Endometrial decidualization and atrophy. * **Hypertension & Contraception:** Avoid Estrogen (COCPs). Progestogen-only methods (LNG-IUS, POP, DMPA) are preferred. * **Mirena Lifespan:** Approved for 5 years (recently extended to 8 years for contraception, but check latest guidelines for HMB).
Explanation: **Explanation:** The primary objective in evaluating any menstrual disorder, especially in an adolescent, is to establish a diagnosis through a systematic approach. **1. Why "Clinical history and examination" is correct:** In a 14-year-old presenting with irregular bleeding (Anovulatory DUB/AUB), the most common cause is an **immature Hypothalamic-Pituitary-Ovarian (HPO) axis**. However, before ordering investigations, a detailed clinical history is mandatory to rule out pregnancy, systemic illness, or medication use. Physical examination (including assessment of secondary sexual characteristics and BMI) helps differentiate between physiological immaturity and pathological conditions like PCOS or thyroid dysfunction. In medical practice, "History and Physical Examination" is always the **first step** in any diagnostic algorithm. **2. Why other options are incorrect:** * **Option A (BT/CT):** While 20% of adolescents with heavy menstrual bleeding may have an underlying bleeding disorder (like von Willebrand disease), these tests are secondary investigations performed only after the initial clinical assessment suggests a coagulopathy. * **Option C (Ultrasound):** USG is useful to check for structural abnormalities (e.g., polycystic ovaries or hematocolpos), but it is not the immediate next step before a clinical evaluation. * **Option D (TLC, DLC, ESR):** These are markers of infection or inflammation. Unless the patient presents with fever or pelvic pain (suggesting PID), these are not routine first-line tests for menstrual irregularities. **Clinical Pearls for NEET-PG:** * **Most common cause of AUB in adolescents:** Anovulation due to HPO axis immaturity (usually takes 2–3 years post-menarche to mature). * **First-line investigation for AUB (General):** Transvaginal Ultrasound (TVS) is the gold standard for structural causes, but clinical history always precedes it. * **Management:** If bleeding is mild, reassurance is sufficient. If severe, hormonal therapy (OCPs) or Tranexamic acid is used. Aspirin is avoided due to the risk of Reye’s syndrome and anti-platelet effects.
Explanation: **Explanation:** Dysfunctional Uterine Bleeding (DUB) is a diagnosis of exclusion, most commonly caused by **anovulation**. In anovulatory cycles, there is continuous estrogen stimulation of the endometrium without the stabilizing effect of progesterone (due to the absence of a corpus luteum). This leads to an unstable, thickened endometrium that sheds irregularly and excessively. **1. Why Progesterone is Correct:** Progesterone is the mainstay of medical management for DUB. It acts by converting the proliferative endometrium into a secretory one, stabilizing the endometrial lining, and inducing a "medical curettage" upon withdrawal. In a 32-year-old multiparous woman, cyclic progestogens or a Levonorgestrel-releasing Intrauterine System (LNG-IUS) are first-line treatments to regulate the cycle and reduce blood loss. **2. Why Other Options are Incorrect:** * **Danazol:** While it causes endometrial atrophy, it is rarely used due to significant androgenic side effects (hirsutism, acne, weight gain). It is reserved for resistant cases, not first-line therapy. * **Prostaglandins:** Prostaglandin *inhibitors* (NSAIDs like Mefenamic acid) are used to reduce blood loss, but prostaglandins themselves would worsen uterine cramping and are not a treatment for DUB. * **Endometrial Ablation:** This is a surgical intervention. In a 32-year-old, medical management must be exhausted first. Surgery is generally reserved for women who have completed their family and failed medical therapy. **Clinical Pearls for NEET-PG:** * **DOC for DUB (Acute bleeding):** High-dose Estrogen or OCPs. * **DOC for DUB (Maintenance/Long-term):** LNG-IUS (Mirena) is currently considered the gold standard medical treatment. * **Investigation of Choice:** Transvaginal Ultrasound (TVS) is the initial investigation; however, **Endometrial Biopsy** is mandatory if the patient is >35 years old to rule out endometrial hyperplasia or malignancy.
Explanation: **Explanation:** **Dysfunctional Uterine Bleeding (DUB)**, now often categorized under the PALM-COEIN classification as AUB-O (Ovulatory dysfunction), refers to abnormal uterine bleeding in the absence of any detectable organic pelvic pathology, systemic disease, or pregnancy. **1. Why Postmenopausal period is the correct answer:** DUB is fundamentally a disorder of the **Hypothalamic-Pituitary-Ovarian (HPO) axis**. In the postmenopausal period, the ovaries have failed and the endometrium is typically atrophic. Any bleeding occurring after menopause is considered **Postmenopausal Bleeding (PMB)** and is highly suspicious of malignancy (e.g., Endometrial Carcinoma) or local pathology (e.g., Atrophic Vaginitis). It is **never** classified as DUB, as the hormonal cycling required for DUB no longer exists. **2. Analysis of incorrect options:** * **Adolescence:** DUB is very common here due to an **immature HPO axis**, leading to frequent anovulatory cycles. * **Following childbirth:** The HPO axis takes time to re-establish its rhythm post-delivery, especially during lactation, often resulting in temporary hormonal imbalances and DUB. * **Premenopausal period:** This is the most common age group for DUB. As ovarian reserve declines, cycles become increasingly anovulatory due to erratic estrogen levels and progesterone deficiency. **Clinical Pearls for NEET-PG:** * **Most common cause of DUB:** Anovulation (leads to "unopposed estrogen" action on the endometrium). * **Gold Standard Investigation for DUB (>40 years):** Fractional Curettage or Endometrial Biopsy to rule out endometrial hyperplasia/malignancy. * **Drug of Choice:** In acute heavy bleeding, high-dose Estrogen or Tranexamic acid; for long-term management, the **Levonorgestrel Intrauterine System (LNG-IUS)** is the medical treatment of choice.
Explanation: **Explanation:** Dysfunctional Uterine Bleeding (DUB) is a **diagnosis of exclusion**. It is defined as abnormal uterine bleeding (AUB) that occurs in the absence of any identifiable pelvic pathology, systemic disease, or external interference. The correct answer is **D (All of the above)** because: 1. **Organic causes:** These refer to structural abnormalities of the pelvic organs, such as uterine fibroids, adenomyosis, polyps, or malignancies (the "PALM" criteria in FIGO classification). DUB occurs in a structurally normal uterus. 2. **Systemic causes:** These include coagulopathies (e.g., von Willebrand disease), endocrine disorders (e.g., hypothyroidism, PCOS), or hepatic/renal failure. DUB excludes these systemic influences. 3. **Iatrogenic causes:** This refers to bleeding caused by medical interventions, such as intrauterine devices (IUCDs), hormonal contraceptives, or drugs like anticoagulants and steroids. **Why other options are insufficient:** While A, B, and C are all components of the definition, selecting only one would be incomplete. DUB specifically represents bleeding where the underlying mechanism is an **endocrine dysfunction** (usually anovulation) rather than a physical or external trigger. **High-Yield Clinical Pearls for NEET-PG:** * **FIGO Classification:** The term "DUB" is increasingly being replaced by the **PALM-COEIN** classification. DUB primarily corresponds to the "O" (Ovulatory dysfunction) and "E" (Endometrial) categories. * **Most Common Cause:** In the majority of cases (approx. 80%), DUB is **anovulatory**, commonly seen at the extremes of reproductive life (menarche and perimenopause) due to an un-opposed estrogen state. * **Investigation of Choice:** Transvaginal Ultrasound (TVS) is the initial investigation to rule out organic causes, while Endometrial Biopsy is the gold standard to rule out malignancy in women >35 years.
Explanation: **Explanation:** Primary amenorrhea is a clinical diagnosis made when a young woman has never experienced menarche. According to standard gynecological guidelines (including Williams Gynecology and Berek & Novak), the definition is based on two distinct criteria: 1. **Age 16 years:** If the patient has **normal** secondary sexual characteristics (e.g., breast development, pubic hair) but has not started menstruating. 2. **Age 13 years:** If the patient has **no** secondary sexual characteristics and has not started menstruating. Since the question asks for the general age limit without specifying the status of secondary sexual characteristics, **16 years** is the standard textbook answer for the upper limit of normal menarche. **Analysis of Options:** * **Option A (13 years):** This is the cutoff only if there is a complete absence of secondary sexual development (indicating a possible HPO axis or genetic issue like Turner Syndrome). * **Option B (15 years):** While some modern guidelines (like ACOG) suggest evaluation at 15 to catch disorders earlier, 16 remains the classic benchmark for NEET-PG and standard Indian medical curriculum. * **Option D (18 years):** This was an older definition used decades ago but is now considered far too late for clinical intervention. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of Primary Amenorrhea:** Gonadal dysgenesis (Turner Syndrome, 45,XO). * **Most common cause with normal secondary sexual characteristics:** Müllerian agenesis (Mayer-Rokitansky-Küster-Hauser syndrome). * **First step in evaluation:** Physical examination to assess secondary sexual characteristics and a pelvic ultrasound to confirm the presence or absence of the uterus.
Explanation: **Explanation:** Puberty menorrhagia refers to excessive menstrual bleeding occurring between menarche and 19 years of age. The underlying pathophysiology is almost always an **anovulatory cycle** due to an immature Hypothalamic-Pituitary-Ovarian (HPO) axis. **1. Why Progesterone is the Drug of Choice (DOC):** In anovulatory cycles, there is "unopposed estrogen" action on the endometrium without the stabilizing effect of progesterone (since no corpus luteum is formed). This leads to a fragile, hyperplastic endometrium that sheds irregularly and profusely. Administering **Progesterone** (e.g., Medroxyprogesterone acetate or Norethisterone) stabilizes the endometrial lining and induces a "medical curettage," making it the primary treatment to arrest bleeding and regulate the cycle. **2. Analysis of Incorrect Options:** * **B. Oral Contraceptive Pills (OCPs):** While OCPs are highly effective and often used as second-line or for long-term maintenance, they are generally not the first choice in a young pubertal girl unless progesterone alone fails, due to the desire to allow the HPO axis to mature without exogenous estrogen suppression. * **C. Intrauterine Contraceptive Device (IUCD):** Levonorgestrel-IUS (Mirena) is the DOC for *adult* Menorrhagia (DUB), but it is rarely used as a first-line agent in virgins or adolescents due to insertion difficulties and the invasive nature. * **D. Endometrial Curettage:** This is **contraindicated** in teenagers. It should only be performed as a life-saving measure to stop hemorrhage when medical management fails. **Clinical Pearls for NEET-PG:** * **Most common cause of Puberty Menorrhagia:** Anovulation (Immaturity of HPO axis). * **Most common systemic cause:** Von Willebrand Disease (always screen if bleeding starts from menarche). * **Investigation of Choice:** Pelvic Ultrasound (to rule out PCOS or structural issues). * **Management Goal:** Rule out hematological disorders and stabilize the endometrium using progestogens.
Explanation: To understand this question, we must analyze two parameters: the **cycle length** and the **volume of blood loss**. ### **Why Oligomenorrhea is the Correct Answer** * **Normal Menstrual Cycle:** The standard interval is $28 \pm 7$ days (21–35 days). * **Definition of Oligomenorrhea:** It is defined as infrequent menstruation where the cycle length exceeds **35 days** (but is less than 6 months). * **Blood Loss:** Normal menstrual blood loss (MBL) is **20–80 ml**. In this case, the patient has 20 ml loss, which is within the normal range. * **Conclusion:** Since the volume is normal but the interval is prolonged (35 days or more), the condition is classified as **Oligomenorrhea**. ### **Analysis of Incorrect Options** * **Metrorrhagia:** Refers to irregular, acyclic bleeding occurring between periods (intermenstrual bleeding). The patient’s cycle here is regular but infrequent. * **Menometrorrhagia:** A combination of heavy menstrual bleeding (menorrhagia) and irregular bleeding (metrorrhagia). It involves both excessive volume and irregular timing. * **Menorrhagia (Hypermenorrhea):** Defined as cyclic bleeding that is excessive in volume (**>80 ml**) or duration (**>7 days**). The patient’s 20 ml loss is normal. ### **NEET-PG High-Yield Pearls** * **Polymenorrhea (Epimenorrhea):** Cycle interval **<21 days**. * **Hypomenorrhea:** MBL **<20 ml** or very short duration of flow. * **Amenorrhea:** Absence of periods for **>6 months** (or 3 cycles in a previously regular woman). * **Most common cause of Oligomenorrhea:** Polycystic Ovary Syndrome (PCOS). * **Gold Standard for measuring MBL:** Alkaline Hematin Method.
Explanation: **Explanation:** The most common cause of **Dysfunctional Uterine Bleeding (DUB)**, particularly in the adolescent and perimenopausal age groups, is **Anovulatory Cycles**. In an anovulatory cycle, a follicle develops and produces **Estrogen**, leading to endometrial proliferation. However, because ovulation does not occur, no **Corpus Luteum** is formed. Consequently, there is a **deficiency of Progesterone**. Without progesterone to stabilize and mature the endometrium (secretory transformation), the lining continues to grow under the influence of unopposed estrogen until it outgrows its blood supply. This leads to irregular, heavy, and prolonged "estrogen breakthrough bleeding." **Analysis of Options:** * **A. Estrogen:** In DUB, estrogen is typically present and often "unopposed." It is the excess or prolonged action of estrogen relative to progesterone that causes the pathology. * **C. Thyroxine:** While hypothyroidism can cause menstrual irregularities (menorrhagia), DUB is primarily defined as abnormal bleeding in the absence of systemic or organic disease. Thyroxine deficiency is a systemic cause, not the primary hormonal deficit defining DUB. * **D. ACTH:** Adrenocorticotropic hormone abnormalities relate to adrenal disorders (like Cushing’s or Addison’s), which are secondary causes of menstrual dysfunction rather than the primary mechanism of DUB. **High-Yield Clinical Pearls for NEET-PG:** * **Definition:** DUB is a diagnosis of exclusion. It is now classified under the **FIGO PALM-COEIN** nomenclature as "AUB-O" (Ovulatory dysfunction). * **Histology:** The classic finding in DUB/Anovulation is **Hyperplastic or Proliferative endometrium**. * **Drug of Choice:** For acute bleeding in DUB, high-dose Estrogen or Progesterone can be used; for long-term management of anovulatory DUB, **Combined Oral Contraceptive Pills (OCPs)** or the **Levonorgestrel-releasing Intrauterine System (LNG-IUS)** are preferred.
Explanation: ### Explanation **Correct Answer: D. Mittelschmerz** **Why it is correct:** The term **Mittelschmerz** (German for "middle pain") refers to mid-cycle ovulatory pain. The clinical presentation in this case is classic: a young woman experiencing sharp, unilateral lower abdominal pain occurring approximately **14 days before menses** (the timing of ovulation). * **Mechanism:** It is attributed to the rapid expansion of the dominant follicle, its rupture, or the irritation of the peritoneum by the released follicular fluid and blood. * **Key Feature:** It is typically short-lived (minutes to 48 hours) and occurs mid-cycle. **Why the other options are incorrect:** * **A. Endometriosis:** Pain is usually chronic and presents as **secondary dysmenorrhea** (pain during menses), deep dyspareunia, or chronic pelvic pain. It does not typically occur solely as a sharp mid-cycle event. * **B. Dysmenorrhea:** This refers to painful menstruation. **Primary dysmenorrhea** occurs *with* the onset of menses due to prostaglandin (PGF2α) release, not two weeks prior. * **C. Pelvic Tuberculosis:** This usually presents with chronic pelvic pain, menstrual irregularities (often oligomenorrhea or amenorrhea), and constitutional symptoms like low-grade fever and weight loss. **High-Yield NEET-PG Pearls:** * **Timing:** Always calculate the cycle day. In a 28-day cycle, pain on day 14 is Mittelschmerz. * **Diagnosis:** It is a diagnosis of exclusion. No specific treatment is required other than reassurance or simple analgesics. * **Suppression:** If the pain is severe and recurrent, **Combined Oral Contraceptive Pills (OCPs)** are the treatment of choice as they inhibit ovulation. * **Differential:** If the pain is sudden and severe with signs of shock, consider a **ruptured ectopic pregnancy** or **ruptured corpus luteum cyst**.
Normal Menstrual Physiology
Practice Questions
Primary Dysmenorrhea
Practice Questions
Secondary Dysmenorrhea
Practice Questions
Premenstrual Syndrome and PMDD
Practice Questions
Primary Amenorrhea
Practice Questions
Secondary Amenorrhea
Practice Questions
Polycystic Ovary Syndrome
Practice Questions
Abnormal Uterine Bleeding: Classification
Practice Questions
Evaluation of Menstrual Disorders
Practice Questions
Management Approaches to Menstrual Disorders
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free